As previously reported, BofA initiated coverage of Ocular Therapeutix with a Buy rating and $15 price target. Ocular is developing a pipeline of sustained release drug therapies leveraging its proprietary Elutyx platform with potential ophthalmology indications, notes the analyst, who thinks lead asset Axpaxli has the potential for a differentiated profile in wet age-related macular degeneration, or wAMD.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on OCUL:
- Ocular Therapeutix Updates Phase 3 SOL Trial Protocol
- Ocular Therapeutix announces FDA agreement to amend SPA for AXPAXLI
- Summer Road raises Ocular Therapeutix stake by $5.0M
- Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
- Ocular Therapeutix 30.8M share Spot Secondary priced at $3.25
